Table 1 Clinical characteristics of subjects

Number of patients

146

Mini-mental state examination score

27.8 ± 3.1

Male, n (%)

111 (76.0%)

Age, y

70.9 ± 8.6

Body mass index, kg/m²

23.5 ± 3.4

Systolic blood pressure, mmHg

127 ± 16.3

Diastolic blood pressure, mmHg

71 ± 11.6

Low-density lipoprotein cholesterol, mg/dL

96.0 ± 34.4

Triglycerides, mg/dL

124.5 ± 70.3

High-density lipoprotein cholesterol, mg/dL

55.0 ± 14.7

HbA1c, %

6.7 ± 5.5

Fasting plasma blood glucose, mg/dL

130.0 ± 58.7

Brain natriuretic peptide, pg/mL

151.6 ± 274.2

Left ventricular ejection fraction, %

58.6 ± 11.2

Fatty acids

Docosahexaenoic acid, μg/mL

132.5 ± 52.2

Eicosapentaenoic acid, μg/mL

68.9 ± 40.4

Arachidonic acid, μg/mL

173.0 ± 43.4

Dihomogammalinolenic acid, μg/mL

34.5 ± 11.4

Complications

Dyslipidemia, n (%)

126 (86.3%)

Hypertension, n (%)

131 (89.7%)

Diabetes mellitus, n (%)

80 (54.8%)

Cerebrovascular disease, n (%)

25 (17.1%)

Smoking, n (%)

108 (74.0%)

Drugs

ACEI/ARB, n (%)

91 (62.3%)

β-blockers, n (%)

53 (36.3%)

Calcium channel blockers, n (%)

62 (42.5%)

Statins, n (%)

123 (84.2%)

Ezetimibe, n (%)

8 (5.5%)

Diuretics loop, n (%)

27 (18.5%)

Mineralocorticoid antagonists, n (%)

7 (4.8%)